XTX Topco Ltd Sells 13,834 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

XTX Topco Ltd lessened its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 25.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 39,542 shares of the company’s stock after selling 13,834 shares during the period. XTX Topco Ltd’s holdings in Amylyx Pharmaceuticals were worth $140,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its position in Amylyx Pharmaceuticals by 18.3% during the first quarter. China Universal Asset Management Co. Ltd. now owns 17,188 shares of the company’s stock valued at $61,000 after acquiring an additional 2,653 shares during the last quarter. Valeo Financial Advisors LLC bought a new position in Amylyx Pharmaceuticals during the first quarter valued at $35,000. Northern Trust Corp increased its position in Amylyx Pharmaceuticals by 11.8% during the fourth quarter. Northern Trust Corp now owns 106,564 shares of the company’s stock valued at $403,000 after acquiring an additional 11,214 shares during the last quarter. Alpine Global Management LLC bought a new position in Amylyx Pharmaceuticals during the fourth quarter valued at $45,000. Finally, Alps Advisors Inc. increased its position in Amylyx Pharmaceuticals by 22.0% during the first quarter. Alps Advisors Inc. now owns 67,597 shares of the company’s stock valued at $239,000 after acquiring an additional 12,167 shares during the last quarter. Institutional investors own 95.84% of the company’s stock.

Analyst Upgrades and Downgrades

AMLX has been the topic of a number of analyst reports. Leerink Partnrs upgraded shares of Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 6th. Guggenheim began coverage on shares of Amylyx Pharmaceuticals in a research report on Tuesday, June 24th. They set a “buy” rating and a $17.00 price objective on the stock. Leerink Partners upgraded shares of Amylyx Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $4.00 to $10.00 in a report on Wednesday, May 7th. The Goldman Sachs Group upgraded shares of Amylyx Pharmaceuticals to a “buy” rating and set a $10.00 price target on the stock in a report on Thursday, July 10th. Finally, UBS Group upgraded shares of Amylyx Pharmaceuticals to a “hold” rating in a report on Tuesday, June 24th. Three equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.75.

Amylyx Pharmaceuticals Price Performance

NASDAQ:AMLX opened at $8.41 on Friday. Amylyx Pharmaceuticals, Inc. has a 1-year low of $2.05 and a 1-year high of $8.72. The company has a 50-day moving average of $7.05 and a 200 day moving average of $5.10. The firm has a market cap of $749.92 million, a PE ratio of -3.36 and a beta of -0.46.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.02). Sell-side analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.